what this node claims
AlphaFold metrics / MTOR
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
53%
low debt pressure
21%
78%structureusable
pLDDT 77.97
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 77.97
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 77.97
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
2549 residues / min 23.27 / max 94.56 / source alphafold db
Very high
10.7%
272 residues / >=90
Confident
71.5%
1822 residues / 70-89
Low
8.0%
204 residues / 50-69
Very low
9.8%
251 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 2549 of 2549 residues.
- residues 285-358 / mean 36.26
- residues 2423-2494 / mean 40.7
- residues 1811-1871 / mean 39.08
- residues 1219-1260 / mean 49.55
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.